Editor’s Note
Primoris International accelerates its Asia expansion following the second PRISM symposium at IMCAS Asia 2026 in Bangkok. The event featured KOLs from Korea and Thailand sharing clinical insights on the company’s exosome portfolio, including P198 ExoHealer and P198 ExoNature. Primoris now holds partnerships in over 50 countries.
Primoris International is accelerating its expansion in Asia after holding the second edition of PRISM in IMCAS Asia 2026 (Primoris Symposium Medical Summit), the company’s own symposium held alongside the congress. The company’s exosome portfolio is built around two products: P198 ExoHealer, formulated with exosomes derived from human umbilical cord blood stem cells, and P198 ExoNature, which the company describes as a plant-derived exosome product sourced from Korean ginseng (Panax ginseng). According to the company, Primoris currently maintains partnerships in more than 50 countries.
Held on June 19 in Bangkok, this edition of PRISM brought together key opinion leaders (KOLs) from Korea and Thailand to share real-world clinical experience and practical know-how from both countries. The company said it sought to go beyond straightforward product presentations, placing greater emphasis on networking and panel discussions aimed at deepening its relationships with physicians. Alongside the P198 line, Primoris also showcased its PLA-based biostimulator, coll:Re, and its hybrid aesthetic line, Epiglow, at IMCAS Asia.
For exosome products, regulatory requirements vary according to the source material as well as product classification and intended use. Under the EU Cosmetics Regulation, cells, tissues or products of human origin are listed among the substances prohibited in cosmetic products. In the United States, the FDA states that exosomes used to treat diseases or conditions in humans are generally regulated as drugs and biological products subject to premarket review and approval, and that there are currently no FDA-approved exosome products.
In an interview on the show floor in Bangkok, Seohyun Park, Director of External Relations at Primoris International, discussed the company’s two-track exosome portfolio for divergent regulatory environments, along with the medical education and training it provides after the sale.
It’s a pleasure to be here. I’m Seohyun Park, Director of External Relations at Primoris International. The External Relations Division focuses on two main areas. First, we oversee the company’s international communications and partnerships. Second, we run a global webinar program. We regularly share clinical results and practical know-how with physicians around the world, creating opportunities for shared learning and helping them deepen their understanding of our products.
This is the second PRISM symposium we’ve held, following Paris. What matters most to us is networking. We create a setting where we can meet a wide range of physicians, formally present clinical results from the use of our products and exchange real-world experience with our KOLs — including how they use the products, the outcomes they have seen and their practical know-how and tips — so that everyone can learn and grow together. It also gives us an opportunity to strengthen those relationships. Following Paris, we chose Thailand for the second edition. Thailand is, in many ways, one of Asia’s major hubs, so we see it as an opportunity to meet new physicians and build new connections.
What we value most is going beyond product introductions and product features alone, to show how the products are actually used in clinical practice. That’s why we make a point of assembling a diverse group of KOLs. To share how Korean physicians use the products and how Thai physicians apply them, we put together a varied panel. The session we place particular importance on is the panel discussion. The panelists discuss two or three topics, speaking candidly about their perspectives, where they agree and whether they have had similar experiences. It’s a chance for them to speak freely about the experience they have built up in this industry.
Local partners understand each country’s regulatory requirements and local practices best, so we communicate closely with them to determine the most appropriate approach. The strategy itself is quite straightforward: where human-derived products are permitted, we focus primarily on ExoHealer; in other markets, we lead with ExoNature, for which we are continuing to generate clinical evidence.
Search keyword: skin booster
